SCHEDULE 13G: Poplar Point Capital Discloses 7.7% Passive Stake in NovaBay Pharmaceuticals

Poplar Point Capital Management LLC and its affiliates have disclosed a passive beneficial ownership of 7.7% in NovaBay Pharmaceuticals, Inc. common stock.

Summary

• Poplar Point Capital Management LLC, Poplar Point Capital Partners LP, Poplar Point Capital GP LLC, and Jad Fakhry (collectively, the "Reporting Persons") have jointly filed a Schedule 13G.
• The filing discloses beneficial ownership of 378,297 shares of NovaBay Pharmaceuticals, Inc. Common Stock.
• This ownership represents approximately 7.7% of NovaBay Pharmaceuticals' outstanding Common Stock.
• The percentage is based on 4,885,693 shares of Common Stock outstanding as of November 4, 2024, as reported in NovaBay's Quarterly Report on Form 10-Q.
• The Reporting Persons hold shared voting and shared dispositive power over all 378,297 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would significantly alter the sentiment towards the company, as the stake is explicitly passive.

Positives

• A significant institutional investor, Poplar Point Capital, has taken a notable 7.7% stake in NovaBay Pharmaceuticals, which could be viewed as a vote of confidence in the company's long-term prospects.
• The filing explicitly states the stake is passive, indicating no immediate intent to influence or change control of the company.

Future Outlook

The Schedule 13G filing does not contain any forward-looking statements or guidance regarding NovaBay Pharmaceuticals, Inc.'s future performance or strategic direction. It is solely a disclosure of beneficial ownership by an investment entity.

Industry Context

This filing is a routine disclosure of a passive investment stake by an asset manager in a publicly traded company. It does not provide specific insights into broader industry trends or competitive dynamics within the pharmaceutical sector, but rather reflects an investment decision by Poplar Point Capital.

Stakeholder Impact

• Shareholders: The disclosure informs existing and potential shareholders about a significant institutional investor's stake, which can influence market perception and liquidity.

Key Dates

Keywords

NovaBay Pharmaceuticals, Poplar Point Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Passive Stake, SEC Filing